Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

NCT02181738 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

294

Enrollment

INDUSTRY

Sponsor class

Conditions

Hodgkin Disease

Interventions

DRUG: Nivolumab
DRUG: Doxorubicin
DRUG: Vinblastine
DRUG: Dacarbazine

Sponsor

Bristol-Myers Squibb